Complete Pharmacy and Medical Solutions, LLC. – FDA 483, Feb 23, 2017
This FDA Form 483 document details observations from an inspection of an outsourcing facility. The inspection revealed two primary violations related to drug product stability and labeling.
Firstly, the facility's stability testing results are not being utilized to determine expiration dates for sterile compounded drug products. The facility lacks analytical and sterility data to support the Beyond Use Dates (BUDs) assigned to these products. While the firm stated their BUDs are based on literature, this information is not specific to their operations, such as container closure data. This indicates a deficiency in their quality system regarding stability programs and data-driven BUD assignments.
Secondly, the labels of the outsourcing facility's drug products do not include all information required by section 503B(a)(10)(A) and (B) of the Federal Food, Drug, and Cosmetic Act. Specifically, the drug product label for "HCG 125 IU/0.5 ml, 0.5 ml pre-filled syringe" does not include the information required by section 503B(a)(10)(A). Additionally, the statement "Office Use Only" is missing from the drug product labels, which is a requirement under section 503B(a)(10)(B). These labeling deficiencies have direct business and operational implications, as non-compliant labels can lead to product recalls or regulatory actions.
- Inspection date
- February 23, 2017
- Product type
- Drugs
ID · 654c66d1-7ebb-4380-a244-a0f45c89decd
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.